Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and St Hilda's College are delighted to announce the creation of a new Chair of Clinical Therapeutics thanks to initial, generous, philanthropic support from Professor John Climax. The donation was confirmed at a signing ceremony on Friday 15th December 2017.

Left to Right: Sir Gordon Duff, Principal of St Hilda's College; Professor John Climax; Professor Andrew Carr, Head of NDORMS; Dr Sarah Norman, Senior Tutor, St Hilda's College. Photo credit John Cairns

Through the establishment of this Chair, Oxford will be in a position to address a significant challenge facing universities today: how to translate novel therapies quickly and sustainably from laboratory to clinic.

Under their leadership, the University will establish a new Centre for Clinical Therapeutics, based within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), headed by Professor Andrew Carr. Through this centre, the Chair will work to develop close partnerships within Oxford, and more widely with the pharmaceutical, biotechnology and diagnostics industries, in order to drive new drug treatments through early phase clinical trials.

In addition to funding the Chair, the gift will be used to endow new Fellowships in Clinical Therapeutics. This will open the doors of opportunity to many early and mid-career clinical scientists, enabling them to develop their expertise and practical experience in early phase clinical trials at Oxford. Both the Chair and Fellowships will be associated with St Hilda's College.

Read more (on Oxford Thinking website)      

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.